In recent years, the role of pathology in breast cancer has changed dramatically. Currently, it no longer has a purely diagnostic role, based exclusively on morphology. Pathologists are now asked to provide some information about prognostic and predictive factors, in other words about the risk assessment and the choice of the best treatment, according to Veronesi’s paradigm: “from maximum tolerable treatment to minimum effective treatment”. These changes can be summarized in this way: In the past we were dealing with “what to treat”, now we are dealing with “how to treat”, aiming at dealing with “whom to treat”.

Breast cancer pathology / Mastropasqua, M. G.. - (2013), pp. 45-53. [10.1007/978-88-470-2652-0_4]

Breast cancer pathology

Mastropasqua M. G.
2013-01-01

Abstract

In recent years, the role of pathology in breast cancer has changed dramatically. Currently, it no longer has a purely diagnostic role, based exclusively on morphology. Pathologists are now asked to provide some information about prognostic and predictive factors, in other words about the risk assessment and the choice of the best treatment, according to Veronesi’s paradigm: “from maximum tolerable treatment to minimum effective treatment”. These changes can be summarized in this way: In the past we were dealing with “what to treat”, now we are dealing with “how to treat”, aiming at dealing with “whom to treat”.
2013
978-88-470-2651-3
Handling
Human epidermal growth factor receptor 2 status
Ki67
Oestrogen and progesterone receptors
Pathology
Sentinel lymph node
Tnm staging
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/188267
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact